Eltrombopag reduces clinically relevant thrombocytopenic events in higher risk MDS and AML.

Mednet Member

Medical Oncology · Albert Einstein College of Medicine

My choice of first-line therapy for high-risk MDS patients that are not transplant candidates tends to still be a hypomethylating agent (HMA). I send a myeloid molecular profile on all my MDS patients and use the p53 mutation status to make a decision regarding azacitidine vs. decitabine use. For pa...